Popular Articles
Cellulite Treatment

Nexavar® In Combination With Chemotherapy Shown To Extend Progression-Free Survival In Patients With Advanced Breast Cancer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that their first cooperative group-sponsored randomized Phase II trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar® (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Study findings demonstrated that the median progression-free survival was extended in patients treated with Nexavar and capecitabine compared to patients receiving capecitabine and placebo. These results were statistically significant (p-value = 0.0006). In this trial, the safety and tolerability of the combination was as expected and did not show any new or unexpected toxicities. A complete data analysis from this study is expected to be presented at an upcoming scientific meeting.
generic viagra online
New Molecular Pathway For Targeting Cancer, Disease Discovered By UCLA Researchers
A UCLA study has identified a way to turn off a key signaling pathway involved in physiological processes that can also stimulate the development of cancer and other diseases. The findings may lead to new treatments and targeted drugs using this approach.
News of the day
How Children View And Treat Their Peers With Undesirable Characteristics: K-State Study
A study by Kansas State University researchers is looking at how children perceive and interact with peers who have various undesirable characteristics, such as being overweight or aggressive.
Cardiovascular

Forecasting Cancer Recurrence

Two people with the same kind of cancer who receive the exact same treatment may nevertheless have different chances of their tumors coming back years later. Now a team of scientists has developed a computer model that predicts cancer recurrence in an individual based on how her tumor changes size in response to the first rounds of radiation therapy. The team, headed by Jian Z. Wang, director of the Radiation Response Modeling Program at the James Cancer Hospital and Solove Research Institute of Ohio State University in Columbus, will present the findings at the 51st Annual Meeting of the American Association of Physicists in Medicine (AAPM) in Anaheim, California. The leading author, Zhibin Huang, has been selected as this meeting"s winner of the Jack Fowler Junior Investigator"s Competition. Huang and colleagues at Ohio State University studied 80 women with cervical cancer who were diagnosed with tumors ranging from the size of a marble to the size of a grapefruit. Each woman was treated with a course of radiation therapy -- beams of energy that destroyed the cancerous cells in her pelvis. After few weeks of radiation treatment, the volume of each shrinking tumor was measured using an MRI scanner. By fitting a mathematical model to this data, Huang calculated two things important for understanding how the tumors were responding to the radiotherapy: the fraction of cancerous cells that survived each of the daily radiation treatments and the amount of time it took each woman"s body to clear away and flush out those cells that were destroyed. The two properties vary from individual to individual and from tumor to tumor. These numbers could be used to predict whether or not a woman"s cervical cancer would come back years after her treatments. If each daily radiation treatment annihilated at least 70 percent of a tumor, a woman had a 30 percent better chance of avoiding recurrence than an individual with a more resistant tumor. Similarly, women whose bodies took longer than 22 days to clear out dead cells after each treatment were almost twice as likely to see their tumors reappear down the road. The results, presented at this year"s AAPM meeting, suggest that not all cervical cancers are the same. To improve treatment, said Wang, patients should be grouped based on whether their tumors are radioresistant or radiosensitive. Other kinds of cancer could also benefit from this approach, says Nina A. Mayr, a professor of radiation oncology at the Ohio State University James Cancer Hospital and Solove Research Institute. "Using similar techniques, ongoing projects from our group are tackling other cancer sites, such as lung and prostate cancer." ABOUT MEDICAL PHYSICISTS If you ever had a mammogram, ultrasound, X-ray, MRI, PET scan, or known someone treated for cancer, chances are reasonable that a medical physicist was working behind the scenes to make sure the imaging procedure was as effective as possible. Medical physicists help to develop new imaging techniques, improve existing ones, and assure the safety of radiation used in medical procedures in radiology, radiation oncology and nuclear medicine. They collaborate with radiation oncologists to design cancer treatment plans. They provide routine quality assurance and quality control on radiation equipment and procedures to ensure that cancer patients receive the prescribed dose of radiation to the correct location. They also contribute to the development of physics intensive therapeutic techniques, such as the stereotactic radiosurgery and prostate seed implants for cancer to name a few. The annual AAPM meeting is a great re, providing guidance to physicists to implement the latest and greatest technology in a community hospital close to you. ABOUT AAPM The American Association of Physicists in Medicine (AAPM) is a scientific, educational, and professional organization of more than 6,000 medical physicists. Headquarters are located at the American Center for Physics in College Park, MD. Publications include a scientific journal ("Medical Physics"), technical reports, and symposium proceedings. American Institute of Physics (AIP)


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):